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specificities was not occurring. The kinet-
ics of T cells expressing this activated
phenotype also closely match those of
the antigen-specific T cells measured by
ICCS as well as by MHC Class I tetramer
staining. However, YFV-specific and VV-
specific memory T cells soon lose the
CD38+HLA-DR+ and the Ki-67+Bcl-2–
phenotype, and therefore these markers
are only useful for approximating the total
T cell response elicited during the acute
phase of infection. Nonetheless, this pro-
vides food for thought in terms of the real-
ization that the antiviral T cell response
might be larger thanwhatwe canmeasure
through current functional assays such as
IFNg-based ICCS.
There are several questions that remain
unanswered with regard to the study by
Miller et al. (2008). For instance, if intracel-
lular IFNg production ‘‘tags’’ only one-
third of the total virus-specific T cell
response (as measured by an activated
CD38+HLA-DR+ or Ki-67+Bcl-2– T cell
phenotype), then what cytokines, if any,
do the other two-thirds of the CD8+ T cells
make following stimulation with antigen?
Does this mean that the majority of the T
cell response represents non-IFNg pro-
ducers in humans, or is it possible that
our approaches to in vitro stimulation
require further optimization? Others have
commented that because of the multi-
functional nature of heterologous T cell
populations, measurement of any one
cytokine alone could lead to a lower,
more-conservative estimate of the total
antigen-specific T cell response (Seder
et al., 2008). With this in mind, it will be in-
teresting to learn the full spectrum of hu-
man cytokine production profiles that
are elicited following various acute viral
infections in both the effector and the
memory phases of the immune response.
On the basis of the results of the study
by Miller et al. (2008), it appears clear
that virus-specific T cell responses follow-
ing acute infection in humans are larger
than expected and vary substantially de-
pending on the efficiency of the technique
used to measure them. Importantly, both
YFV and VV represent viruses that infect
the host through a peripheral route. It will
be interesting to learn whether respiratory
viral infections such as influenza virus or
respiratory syncytial virus are also capa-
ble of eliciting large frequencies of virus-
specific CD8+ T cells in the bloodstream.
Further in-depth analysis of virus-specific
T cell kinetics will be important, given that
it appears that CD8+ T cell responses de-
cay very rapidly in the short term (i.e., the
first weeks after infection) compared to
the long-term (i.e., months or years after
vaccination [Co et al., 2002; Crotty et al.,
2003; Hammarlund et al., 2003]). Analysis
of T cell responses following booster
vaccination or re-infection will be another
interesting avenue of investigation. To-
gether, these studies will lead to a better
understanding of antiviral T cell respon-
ses and maintenance of immunological
memory in humans.
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Hanna et al. (2008) report in a recent issue of Cell that a defined set of transcription factors can reprogram
mature B cells back to pluripotent stem cells.The stem cell field was stunned two years
ago when Takahashi and Yamanaka dem-
onstrated that the transcription factors
Oct4, Sox2, Klf4, and c-Myc are capable
of reprogramming fibroblasts into what
was termed induced pluripotent stem
(iPS) cells. iPS cells closely resemble606 Immunity 28, May 2008 ª2008 Elsevierembryonic stem (ES) cells in their cellular
phenotype and gene-expression profile
(Takahashi andYamanaka, 2006) andcon-
tribute to the germline when transplanted
into blastocysts (Okita et al., 2007; Wernig
et al., 2007). Because of the low reprog-
ramming efficiency, it remained, however,Inc.unclear whether iPS cells originate from
differentiated fibroblasts or rare stem cells
coexisting in the fibroblast culture. A simi-
lar argument was put forward to explain
the low success of previous somatic cell
nuclear-transfer experiments. Hochedlin-
ger and Jaenisch (2002) subsequently
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PreviewsFigure 1. Reprogramming of B Lymphocytes into iPS Cells
Previous experiments demonstrated that viral expression of Oct4, Sox2, Klf4, and c-Myc (4 Yamanaka transcription factors; 4Y TFs) in mouse embryo fibroblasts
(MEFs) induces the formationof inducedpluripotent stem (iPS) cells (blackarrow). Itwasalso shown that forcedexpressionofC/EBPa inmatureBcells induces their
transdifferentiation intomacrophagesvia inhibitionofPax5 functionandupregulationofPU.1expression (redarrow). Furthermore, conditionalPax5 inactivationwas
shown to allowmature B cells to dedifferentiate into uncommitted lymphoid progenitors (LP, red arrow). Thework of Hanna et al. (2008) now demonstrates that the
4YTFs induce iPScell formation inpro-Bcells andpre-B cells,whereas these factors are ineffective inmatureBcells.MatureBcells areonly induced todevelop into
iPS cells upon coexpression, with the 4Y TFs, of either C/EBPa or an shRNA lentivirus interfering with Pax5 expression (shPax5). Hematopoietic stem cells, HSC.showed, however, that transplantation of
B and T cell nuclei into enucleated oocytes
yielded blastocysts from which ES cells
could be derived. These ES cells gener-
ated mice in which all cells contained
either immunoglobulinorTcell receptor re-
arrangements, showing that differentiated
B andT cells can be reprogrammed to plu-
ripotency by nuclear-transfer experiments
(Hochedlinger and Jaenisch, 2002). This
studyalso raised thepossibility thatmature
lymphoid cells can be reprogrammed by
forced expression of the 4 Yamanaka
(4Y) transcription factors.
This question was addressed in the new
work from the Jaenisch lab, who first stud-
ied the plasticity of immature B cells from
the bone marrow and then that of mature
B cells from the spleen (Hanna et al.,
2008). In brief, the strategy adopted took
advantage of their earlier study, which
showed that fibroblasts from a transgenic
mouse expressing the tetracycline trans-
activator could be reprogrammed into
iPS cells when infected with tetracycline-
inducible lentiviral vectorsof the 4Y factors
and treated with doxycycline. Importantly,
these iPS cells contributed to the forma-
tion of chimeras after injection into blasto-
cysts (Brambrink et al., 2008). In the new
work,Hannaet al. (2008) used the resulting
chimeras as a source of pro-B and pre-B
cells, which in each case constitute a mix-
ture of wild-type B lymphocytes and iPS-cell-derivedB cells containing the four len-
tiviral transgenes. These immature B cells
were cultured on OP9 stromal cells in the
presence of lymphoid cytokines to main-
tain B cell growth and, when stimulated
withdoxycyclin, developedcolonies of ad-
herent cells that became positive for the
ES cell markers alkaline phosphatase and
Nanog (Figure 1). Four of the seven pro-
B-cell-derived iPS cell lines analyzed (iB-
iPS) carried DH-JH rearrangements at the
immunoglobulin heavy chain (IgH) locus.
The presence of a DH-JH rearrangement
does, however, not unequivocally identify
the cell of origin as a pro-B cell because
uncommitted pre-pro-B cells and NK cell
precursors also carry DH-JH rearrange-
ments and are also present within the
B220+c-Kit+ gate used to FACS-sort the
pro-B cells. More convincingly, the pre-
B-cell-derived iB-iPS cell lines exhibited
VH-DJH rearrangements, which were gen-
erated in committed pro-B cells. The iB-
iPS cell lines tested were clearly pluripo-
tent because they induced teratomas
and, upon blastocyst injection, contrib-
uted to the formationofgermlinechimeras.
Biopsies obtained from various tissues of
a chimeric mouse exhibited the same Igh
rearrangements as the iB-iPS cell line
used for producing it. These results there-
fore show that the 4Y factors are sufficient
to reprogram B cell precursors into plurip-
otent cells closely resembling ES cells.ImmIn contrast to the results obtained with
early B cells, mature B cells from the
spleen of adult chimeric mice could not
be reprogrammed with the 4Y factors. In
attempts to overcome this hurdle, the
authorscoexpressedC/EBPa, a transcrip-
tion factor that had been shown to repro-
gram both immature and mature B cells
from the spleen into cells resemblingmac-
rophages (Xie et al., 2004; Figure 1). In-
deed, when C/EBPa was introduced into
eithermature splenic Bcells fromachime-
ric animal containing inducible transgenes
of the 4Y factors, or when mature B cells
were directly coinfected with lentiviruses
of all five factors, B-iPS cell colonies could
be generated (Figure 1). As before, these
B-iPS cells were capable of generating
coat-color chimeras and contributed to
the germline. Each of the nine lines tested
carried a functional rearrangement at the
Igh locus andat oneof thegenesencoding
Igk or Igl light chain, as it is characteristic
of mature B cells. Strikingly, one line even
exhibited somatic hypermutations in the V
regions of their heavy and light chains;
such hypermutations are a hallmark of
germinal center B cells that have under-
gone immunoglobulin affinity maturation
in response to antigen encounter.
Why isC/EBPa soeffective in facilitating
the reprogrammingofmatureBcells?One
possibility is that the necessary key event
to render mature cells susceptible tounity 28, May 2008 ª2008 Elsevier Inc. 607
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cell commitment factor Pax5. Thus, C/
EBPa is known to antagonize the function
of Pax5 during induced transdifferentia-
tion (Xie et al., 2004). In addition, condi-
tional Pax5 inactivation has been shown
to allow mature B cells to dedifferentiate
in vivo into early uncommitted progenitors
with myeloid and T lymphoid differentia-
tion potential (Cobaleda et al., 2007; Fig-
ure 1). This hypothesis is supported by
the finding that an shRNA lentivirus inter-
fering with Pax5 expression was capable
of replacingC/EBPa in the reprogramming
experiments (Hanna et al., 2008; Figure 1).
Hence, the Pax5-dependent transcription
program, whichmaintains the identity of B
cells, needs to be disrupted by ectopic C/
EBPa expression or specific Pax5 knock-
down to allow the reprogramming of ma-
ture B cells into iPS cells by the 4Y factors.
The puzzling finding that the 4Y factors
are sufficient to convert pro-B and pre-B
but notmatureBcells into iPScells implies
that one (or more) of the 4Y factors must
be capable of inactivating Pax5 in early B
lymphocytes. In contrast, C/EBPa can re-
program both early and late B cells (Xie
et al., 2004), thus pointing to different
mechanisms by which the 4Y factor(s)
and C/EBPa inactivate Pax5 function. It
is thus conceivable that the Pax5 tran-
scription complex or hypothetical regula-
tory element(s) of the Pax5 gene escape
the inhibitory action of the 4Y factor(s) in
mature B cells. Because 4Y factor(s)
have recently been shown to also repro-
gram other differentiated cell types such
as hepatocytes and epithelial cells of the608 Immunity 28, May 2008 ª2008 Elsevier Istomach, it is possible that they impose
an ES cell phenotype by a more general
mechanism (Aoi et al., 2008). How this
works would be interesting to know.
Another question raised by the study of
Hanna et al. (2008) is howPax5 downregu-
lation rendersmatureBcells susceptible to
reprogramming. Is it because the cells are
induced by C/EBPa expression to tran-
siently develop into macrophages, which
might be more susceptible to reprogram-
ming because of their adherence? Or, do
mature B cells dedifferentiate to pro-B
and pre-B cells or even further to uncom-
mitted lymphoid progenitors in response
to Pax5 loss? The latter possibility seems
plausible; multipotent progenitors may be
more susceptible to reprogramming be-
cause their chromatin structure and epige-
netic state are likely to bemoreplastic than
those of terminally differentiated cells.
However, the study of Hanna et al. (2008)
also shows that differentiated mature B
cells havesurprisinglyhigh reprogramming
efficiencies (3%). Furthermore, hepato-
cytes and gastric epithelial cells undergo
full reprogrammingmore readily than fibro-
blasts (Aoi et al., 2008), and the nuclei of
postmitotic granulocytes apparently can
be more efficiently reprogrammed than
those of hematopoietic stem cells after
transplantation into oocytes (Sung et al.,
2006). These counterintuitive observations
are a reminder of how little we understand
about the role of transcription factors in ex-
tinguishing one gene-expression program
while activating another one.
The studies of Hanna et al. (2008) have
established a new principle that might benc.key for learning how to overcome the
resistance of differentiated cells to the re-
programming activities of the 4Y factors.
Instead of looking for an additional re-
programming factor acting more proxi-
mally to ES cells, it may bemore advisable
to search for a facilitating transcription
factor among those regulators that func-
tion in the developmental context of the
differentiated cell in question.
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